Readnour Robin Shane's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Sep 8, 2026
- Accession no.
- 0001193125-26-385511
- Filed
- Sep 8, 2026, 7:42 PM ET
- Trade date
- Sep 3-8, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $97.3K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Readnour Robin ShaneCIK 0001914883 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | SSaleDisposed | −2,877 | $6.07F3 | −$17,462.81 | 562,715 | Indirect | |
| Sep 3, 2026 | Common Stock | SSaleDisposed | −3,223 | $6.07F3 | −$19,562.97 | 630,644 | Indirect | |
| Sep 8, 2026 | Common Stock | SSaleDisposed | −4,725 | $6.02F3 | −$28,436.47 | 557,990 | Indirect | |
| Sep 8, 2026 | Common Stock | SSaleDisposed | −5,294 | $6.02F3 | −$31,860.88 | 625,350 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein.
Referenced by the price of 4 transactions in Table I.